Literature DB >> 3042912

Pathogenetic studies of motor fluctuations in Parkinson's disease.

T N Chase1, M M Mouradian, G Fabbrini, J L Juncos.   

Abstract

Pharmacokinetic and pharmacodynamic mechanisms for levodopa have been studied in relation to the pathogenesis of the motor fluctuations which complicate advanced Parkinson's disease. Since levodopa clearance from the general circulation was found to be similar in patients with wearing-off or on-off phenomena and those with a stable response to levodopa, peripheral pharmacokinetic factors are unlikely to be involved. Efficacy half-time for levodopa, on the other hand, was significantly reduced in patients with mainly wearing-off fluctuations in comparison to those manifesting a stable response to oral levodopa; individuals with predominantly on-off phenomenon had an even more extreme reduction in the duration of the antiparkinsonian action of levodopa. Conversion from oral to intravenous levodopa treatment immediately stabilized plasma levodopa levels in both the wearing-off and on-off groups; motor variability also decreased, especially in those with wearing-off phenomenon. During 11 days of continuous intravenous levodopa therapy, additional reductions in motor fluctuations occurred in both groups, but at a significantly faster rate in patients with wearing-off than in those with on-off responses. These results suggest that wearing-off phenomenon may arise as a consequence of the degeneration of dopamine terminals due to natural disease progression with a resultant inability to buffer variations in levodopa availability; on-off phenomenon, may reflect additional postsynaptic dopamine receptor dysregulation, possibly in response to the resultant, nonphysiologic fluctuations in synaptic dopamine.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3042912     DOI: 10.1007/978-3-7091-8954-2_1

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  3 in total

Review 1.  Using liquid levodopa in the treatment of Parkinson's disease. A practical guide.

Authors:  M C Kurth
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 2.  Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.

Authors:  Dirk Deleu; Margaret G Northway; Yolande Hanssens
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

3.  Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease.

Authors:  Will Lee; Andrew H Evans; David R Williams
Journal:  Mov Disord Clin Pract       Date:  2017-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.